Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 306

1.

Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica.

Unizony S, Arias-Urdaneta L, Miloslavsky E, Arvikar S, Khosroshahi A, Keroack B, Stone JR, Stone JH.

Arthritis Care Res (Hoboken). 2012 Nov;64(11):1720-9. doi: 10.1002/acr.21750.

2.

Tocilizumab in refractory aortitis: study on 16 patients and literature review.

Loricera J, Blanco R, Castañeda S, Humbría A, Ortego-Centeno N, Narváez J, Mata C, Melchor S, Aurrecoechea E, Calvo-Alén J, Lluch P, Moll C, Mínguez M, Herrero-Beaumont G, Bravo B, Rubio E, Freire M, Peiró E, González-Vela C, Rueda-Gotor J, Pina T, Palmou-Fontana N, Calvo-Río V, Ortiz-Sanjuán F, González-Gay MÁ.

Clin Exp Rheumatol. 2014 May-Jun;32(3 Suppl 82):S79-89. Epub 2014 May 15.

PMID:
24854377
3.

Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature.

Macchioni P, Boiardi L, Catanoso M, Pulsatelli L, Pipitone N, Meliconi R, Salvarani C.

Semin Arthritis Rheum. 2013 Aug;43(1):113-8. doi: 10.1016/j.semarthrit.2013.01.003. Epub 2013 Feb 20. Review.

PMID:
23433960
4.

Tocilizumab: a novel therapy for patients with large-vessel vasculitis.

Salvarani C, Magnani L, Catanoso M, Pipitone N, Versari A, Dardani L, Pulsatelli L, Meliconi R, Boiardi L.

Rheumatology (Oxford). 2012 Jan;51(1):151-6. doi: 10.1093/rheumatology/ker296. Epub 2011 Nov 10.

5.

Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature.

Kötter I, Henes JC, Wagner AD, Loock J, Gross WL.

Clin Exp Rheumatol. 2012 Jan-Feb;30(1 Suppl 70):S114-29. Epub 2012 May 11. Review.

PMID:
22640655
6.

Treatment of refractory Takayasu arteritis with tocilizumab: 7 Italian patients from a single referral center.

Tombetti E, Franchini S, Papa M, Sabbadini MG, Baldissera E.

J Rheumatol. 2013 Dec;40(12):2047-51. doi: 10.3899/jrheum.130536. Epub 2013 Nov 1.

PMID:
24187104
7.

Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?

van der Veen MJ, Dinant HJ, van Booma-Frankfort C, van Albada-Kuipers GA, Bijlsma JW.

Ann Rheum Dis. 1996 Apr;55(4):218-23. Erratum in: Ann Rheum Dis 1996 Aug;55(8):563.

8.

Clinical outcome of 149 patients with polymyalgia rheumatica and giant cell arteritis.

Bahlas S, Ramos-Remus C, Davis P.

J Rheumatol. 1998 Jan;25(1):99-104.

PMID:
9458211
9.

Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients.

Loricera J, Blanco R, Hernández JL, Castañeda S, Mera A, Pérez-Pampín E, Peiró E, Humbría A, Calvo-Alén J, Aurrecoechea E, Narváez J, Sánchez-Andrade A, Vela P, Díez E, Mata C, Lluch P, Moll C, Hernández Í, Calvo-Río V, Ortiz-Sanjuán F, González-Vela C, Pina T, González-Gay MÁ.

Semin Arthritis Rheum. 2015 Jun;44(6):717-23. doi: 10.1016/j.semarthrit.2014.12.005. Epub 2014 Dec 27.

PMID:
25697557
10.

Tocilizumab, an effective treatment for relapsing giant cell arteritis.

Oliveira F, Butendieck RR, Ginsburg WW, Parikh K, Abril A.

Clin Exp Rheumatol. 2014 May-Jun;32(3 Suppl 82):S76-8. Epub 2014 May 16.

PMID:
24854376
11.

Clinical features of polymyalgia rheumatica and giant cell arteritis.

Salvarani C, Pipitone N, Versari A, Hunder GG.

Nat Rev Rheumatol. 2012 Sep;8(9):509-21. doi: 10.1038/nrrheum.2012.97. Epub 2012 Jul 24. Review.

PMID:
22825731
12.

Predictors for treatment success and expression of glucocorticoid receptor in giant cell arteritis and polymyalgia rheumatica.

Braun N, Fritz P, Rieth A, Schroth W, Kimmel M, Biegger D, Zakim D, Alscher MD.

J Rheumatol. 2009 Oct;36(10):2269-76. doi: 10.3899/jrheum.090075. Epub 2009 Aug 14.

PMID:
19684157
13.

Effective control of polymyalgia rheumatica with tocilizumab.

Al Rashidi A, Hegazi MO, Mohammad SA, Varghese A.

J Clin Rheumatol. 2013 Oct;19(7):400-1. doi: 10.1097/RHU.0b013e3182a6aa0e.

PMID:
24048113
14.

Methotrexate treatment in large vessel vasculitis and polymyalgia rheumatica.

Spies CM, Burmester GR, Buttgereit F.

Clin Exp Rheumatol. 2010 Sep-Oct;28(5 Suppl 61):S172-7. Epub 2010 Oct 28. Review.

PMID:
21044455
15.

Role of peripheral CD8 lymphocytes and soluble IL-2 receptor in predicting the duration of corticosteroid treatment in polymyalgia rheumatica and giant cell arteritis.

Salvarani C, Boiardi L, Macchioni P, Rossi F, Tartoni P, Casadei Maldini M, Mancini R, Beltrandi E, Portioli I.

Ann Rheum Dis. 1995 Aug;54(8):640-4.

16.

Small-vessel vasculitis surrounding an uninflamed temporal artery: a new diagnostic criterion for polymyalgia rheumatica?

Chatelain D, Duhaut P, Loire R, Bosshard S, Pellet H, Piette JC, Sevestre H, Ducroix JP.

Arthritis Rheum. 2008 Aug;58(8):2565-73. doi: 10.1002/art.23700.

17.

Rescue treatment with tocilizumab for Takayasu arteritis resistant to TNF-α blockers.

Salvarani C, Magnani L, Catanoso MG, Pipitone N, Versari A, Dardani L, Pulsatelli L, Meliconi R, Boiardi L.

Clin Exp Rheumatol. 2012 Jan-Feb;30(1 Suppl 70):S90-3. Epub 2012 May 11.

PMID:
22410150
18.

Discontinuation of therapies in polymyalgia rheumatica and giant cell arteritis.

Muratore F, Pipitone N, Hunder GG, Salvarani C.

Clin Exp Rheumatol. 2013 Jul-Aug;31(4 Suppl 78):S86-92. Epub 2013 Oct 4. Review.

PMID:
24129145
19.

[Polymyalgia rheumatica and temporal arteritis].

Vos PA, Bijlsma JW, Derksen RH.

Ned Tijdschr Geneeskd. 2005 Aug 27;149(35):1932-7. Review. Dutch.

PMID:
16159030
20.

Efficacy and safety of anti-interleukin 6 receptor monoclonal antibody (tocilizumab) in Colombian patients with Takayasu arteritis.

Cañas CA, Cañas F, Izquierdo JH, Echeverri AF, Mejía M, Bonilla-Abadía F, Tobón GJ.

J Clin Rheumatol. 2014 Apr;20(3):125-9. doi: 10.1097/RHU.0000000000000098.

PMID:
24662551
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk